MNKD - Sector: Healthcare---Industry: Biotechnology & Drugs

[setravis]

8 Promising Biotech Buyout Targets if Their Products Can Deliver...

The following are a few biotechs with promising products in their pipelines that have made the big boys sit up and take notice. Without further ado, the 8 promising biotechs priced for a buyout if their products can deliver:

MannKind Corporation (MNKD): MannKind Corporation focuses on the development of therapeutic products for patients with diabetes and cancer. MannKind holds the proverbial ace up its sleeve in Afrezza, an inhaled insulin that offers many advantages over injected insulin. These advantages include quicker absorption into the body, levels of glucose control similar to state-of–the-art insulin, and a lower risk of side-effects such as hypoglycemia and weight gain. However, with few other drugs of note in its pipeline, shrinking cash reserves, and close to $2 billion in deficits, Afrezza is likely MannKind's only hope for real profit. Don't expect the product anytime soon though. On January 19th, MannKind Corp. announced that the FDA wouldn't approve Afrezza without further human studies, which could delay approval by two years. According to Morningstar, the FDA is concerned with safety data, labeling changes, and comparability of the firm's latest inhaler with the one used in trials. It also doesn't help that Exubera, an inhaled insulin from Pfizer and Nektar, was pulled from the market in 2007 because of a link to lung cancer. If Afrezza does succeed, the company's $3.69 share price, near its 52-week range low of $3.40, makes it an attractive buy. We just wouldn't hold our breath on it.
Shares currently trade at $3.68

[setravis]

Speculative Drug Developers Take Aim at Blockbuster Status
The Bedford Report Provides Analyst Research on MannKind & Keryx Biopharmaceuticals

Press Release Source: The Bedford Report On Wednesday April 13, 2011, 8:16 am EDT
NEW YORK, NY--(Marketwire - 04/13/11) - There is plenty of optimism surrounding the biotech sector as firmer pricing and new products have improved sales and earnings trends. Meanwhile, younger, more speculative firms continue to garner significant attention with potential blockbuster products working their way through the regulatory process. The Bedford Report examines the outlook for companies in the Biotechnology Industry and provides research reports on MannKind Corporation (NASDAQ:MNKD - News) and Keryx Biopharmaceuticals Inc. (NASDAQ:KERX - News). Access to the full company reports can be found at:

www.bedfordreport.com/2011-04-MNKD

www.bedfordreport.com/2011-04-KERX

MannKind Corporation has been seeking FDA approval for an inhalable form of insulin called Afrezza. Shares of the company were sent plummeting earlier this year after the FDA asked for two new studies of the device in patients with Type 1 and Type 2 diabetes. Alfred Mann -- the company's founder -- was still optimistic and encouraged by the fact the FDA has not asked for anything other than these bridging studies, in terms of clinical work.

Keryx Biopharmaceuticals develops pharmaceuticals for the treatment of diseases such as diabetes, renal disease and cancer. The company's oral, iron-based drug "Zerenex" is in phase III testing under a Special Protocol Assessment agreement with the FDA as a treatment for elevated phosphate levels in patients with end-stage renal disease.

The Bedford Report releases regular market updates on the Healthcare Sector so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.bedfordreport.com and get exclusive access to our numerous analyst reports and industry newsletters.

IMS Health, a leading research and analytical firm serving the pharmaceutical and medical industries, projects an increase in worldwide biotech growth in 2011 of between 5 and 7 percent, with a similar outlook stretching out to 2015. Emerging markets such as China, India, and Brazil are expected to contribute significantly to this growth. Sales growth of 15 percent is forecast in emerging markets, many of which are benefitting from increased government spending on healthcare and broader private health coverage for workers.

The Bedford Report provides Analyst Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned publicly traded companies. The Bedford Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.bedfordreport.com/disclaimer

Contact:
Contact: The Bedford ReportEmail Contact